Read More

DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023

DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today

DMK

Read More

Intercept Announces New Phase 2 Data Showing Significant Impact Of OCA-Bezafibrate Combination On Normalization Of Multiple Key Biomarkers Of PBC-Induced Liver Damage At AASLD The Liver Meeting 2023

Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5

ICPT